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Abstract
Paediatric inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the digestive tract, comprising of Crohn’s
disease (CD), ulcerative colitis (UC), and, where classification is undetermined, inflammatory bowel disease unclassified
(IBDU). Paediatric IBD incidence is increasing globally, with prevalence highest in the developed world. Though no specific
causative agent has been identified for paediatric IBD, it is believed that a number of factors may contribute to the development of
the disease, including genetics and the environment. Another potential component in the development of IBD is the microbiota in
the digestive tract, particularly the gut. While the exact role that the microbiome plays in IBD is unclear, many studies acknowl-
edge the complex relationship between the gut bacteria and pathogenesis of IBD. In this review, we look at the increasing number
of studies investigating the role the microbiome and other biomes play in paediatric patients with IBD, particularly changes
associated with IBD, varying disease states, and therapeutics. The paediatric IBD microbiome is significantly different to that of
healthy children, with decreased diversity and differences in bacterial composition (such as a decrease in Firmicutes). Changes in
the microbiome relating to various treatments of IBD and disease severity have also been observed in multiple studies. Changes
in diversity and composition may also extend to other biomes in paediatric IBD, such as the virome and the mycobiome.
Research into biome differences in IBD paediatric patients may help progress our understanding of the aetiology of the disease.
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Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are idiopath-
ic inflammatory bowel diseases (IBD).Wilhelm Fabry discov-
ered Crohn’s disease in 1623, and its features were more de-
finitively described by T.K. Dalziel in Scotland in 1913 [1]
though it was later described by and named Burril B Crohn in
1932. The British physician Sir Samuel Wilks was the first to
describe ulcerative colitis in 1859 [2]. Both CD and UC can
occur in adults and children. There are a number of proposed
risk factors in the development of IBD. One such potential risk
factor or perhaps, as some have suggested, even a causative
agent, is perturbedmicrobiota in the intestine. This reviewwill
look at the role of the microbiome in paediatric patients with
IBD, outlining the findings thus far and the potential future of
this particular area of research.
Pathology of Crohn’s Disease and Ulcerative
Colitis
Primary Effects
Although both Crohn’s disease (CD) and ulcerative colitis
(UC) are chronic inflammatory disorders of the gastrointesti-
nal tract, they have unique features which distinguish them as
distinct diseases. UC is a mucosal disease which originates in
the rectum and may extend proximally. The ileum is generally
not involved, and diffuse inflammation (a microscopic feature
of UC) is confined to the mucosa and submucosa [3, 4]. CD
shows patchy and segmental distribution and may involve any
part of the gastrointestinal tract [3–5], though most commonly
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presents in the ileum. Granulomas and fissures are microscop-
ic features often distinguishing CD from UC [3, 5].
Secondary Effects
In addition to the gastrointestinal symptoms, IBD is also as-
sociated with a set of additional risks. Patients with IBD are at
an increased risk of cancer, particularly colon cancer (UC and
CD) and small bowel cancer (CD) (for paediatric patients
development of such cancers may occur when they reach
adulthood). The risk between these intestinal cancers and
IBD is influenced by multiple factors, including the extent
of the disease, the age of the patient at diagnosis, and the
length of time since the patient was diagnosed [5], suggesting
the possibility that paediatric patients may be at an even great-
er risk given the permanency of the diseases. A study of
Danish and Finnish paediatric IBD patients found them to be
2.5 times as likely to develop cancer as the general population
[6], and similar findings were reported in a study of Swedish
paediatric patients by Olen et al. [7]. Patients with IBD may
also suffer with extra intestinal manifestations linked to IBD
such as arthritis, liver disease, and skin or ocular complica-
tions. These manifestations are common in children and
adults, but in children, they may precede gastrointestinal
symptoms [5].
Paediatric patients are also at risk of growth failure [5],
which occurs in approximately 40% of CD and 10% of UC
paediatric patients [8]. Approximately, a fifth of paediatric CD
patients achieved a height significantly less than the expected
target (>8 cm below target height) [9]. Consequently, steroids
used to treat UC and CD in adults may not always be appro-
priate in paediatric patients due to the risk of growth retarda-
tion associated with these medications, especially in cases of
children already suffering malnutrition due to IBD.
Malnutrition is a more common occurrence in CD than UC;
however, in recent years, an increased number of children
diagnosed with IBD are either overweight or obese, following
global trends of the general paediatric population [10]. Rates
of obesity for children with UC were similar to the general
population; however, lower rates were observed in children
with CD.
Furthermore, psychosocial stress is often an additional
side effect of IBD in children and adults. Absence from
school, isolation from peers, extended hospital stays, and
familial stress may all be contributing factors to this.
Children with IBD were found to be at a higher risk of
depressive disorders [11] and more likely to report a low-
er health related quality of life [12]. Danish and Finnish
IBD patients who had childhood onset IBD have been
found to be more likely to die from suicide then the gen-
eral population, which may be reflective of this increased
probability of depressive disorders [6].
Incidence and Prevalence of IBD
Prevalence of CD and UC are highest in the developed world,
particularly North America and Europe [13], and the inci-
dence of IBD appears to be increasing, particularly in devel-
oping countries [14]. Approximately, 20 to 25% of patients
present with IBD before the age of 20 [5, 8, 15], with approx-
imately 4% of paediatric IBD presenting before the age of 5,
and 10% before the age of 10 [8, 15]. For paediatric IBD,
many studies suggest an increasing prevalence of paediatric
IBD, even in the developed world [16, 17]. A study of paedi-
atric IBD in Ontario found that prevalence per 100,000 of the
population had increased from 42.1 in 1994 to 56.3 in 2005
and incidence rates per 100,000 increased from 9.5 in 1994 to
11.4 in 2005 [18].
Potential Risk Factors for IBD
A major risk factor influencing the incidence of IBD is its
genetic component, with >200 IBD associated loci [19].
Familial studies have demonstrated the genetic link of IBD
[20], with up to 14% of IBD patients having a family member
also suffering from the disease [21]. These genetic links can
be seen in Jewish populations, where both CD and UC are
found to more common in people of Jewish descent [2], and
familial risk being increased for Jews vs non-Jews [22].
Increased risk is also related to geography with the preva-
lence and incidence of IBD higher in developed countries
though this is most likely due to environmental risk factors
such as industrialisation (leading to increases in pollution,
such as air pollution [23]), sanitation (the hygiene hypothesis
[24, 25]), and western diet and lifestyle.
A potential risk factor in IBD which has seen increased
interest is the role of the microbiota in IBD, particularly the
gut microbiota. Studies involving the composition and abun-
dance of microorganisms in the gut (or ‘gut microbiome’) in
IBD have revealed differences between healthy individuals
and patients with IBD [26], both in colon [27] and stool sam-
ples [28], as well as between different disease states and vary-
ing with disease severity [29–31]. These differences can be
seen in both children and adult IBD patients; however, for the
purpose of this review, the focus will be on paediatric IBD.
The Paediatric Microbiome
The microorganisms that colonise the human gut are often
collectively referred to as the gut microbiome. When a child
is born, the gut is initially colonised by environmental mi-
crobes, mainly from the mother’s microbiome, that may be
the vaginal (or faecal) microbiome or the skin microbiome if
born via Caesarean section [32]. The phyla Firmicutes,
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Proteobacteria, Bacteroidetes, and the phylum Actinobacteria
(especially the genus Bifidobacterium) generally colonise the
infant gut [33, 34]. The two most common phyla in the adult
gut, Bacteroidetes and Firmicutes, generally dominate by the
end of the first year of the infant’s life, though the healthy
infant gut continues to undergo dramatic composition changes
before stabilising at about age three or four [35]. Most studies
agree that the infant gut microbiome closely resembles the
adult gut microbiome by about age 3 years [36, 37].
Conversely, some studies argue that there are differences be-
tween the adult and child gut microbiome, such as increased
abundances of Firmicutes and Actinobacteria observed in
children compared to adults [38]. In addition, decreased
Bacteroidetes (in pre-adolescent children) [38] and increased
numbers of Bifidobacteria were seen in paediatric samples
(ages 1–18) [38–40]. Potential differences in the microbiome
of healthy children when compared to adults may also suggest
that the microbiome of paediatric IBD may potentially differ
to adult IBD microbiomes.
The Gut Microbiome in Crohn’s Disease
and Ulcerative Colitis
While the exact role the microbiome plays in IBD is un-
clear, many studies acknowledge the complex relationship
between the gut bacteria and pathogenesis of IBD, as
reviewed by Wilson and Russell [41]. Various studies have
investigated the unique aspects of CD and UC in paediatric
patients. Increased numbers of Escherichia coli were ob-
served in paediatric CD stool samples but not in UC [42].
Faecalibacterium prausnitzii has been observed to be de-
creased in paediatric CD stool samples [42, 43] and in-
creased in colonic biopsies [44] of paediatric CD compared
to UC and controls. In contrast, Olbjørn and colleagues
found only Mycoplasma hominis differed between paedi-
atric CD and UC. Furthermore, the representatives of fam-
ilies Lachnospiraceae and Coriobacteriaceae were ob-
served to be decreased in both paediatric CD and UC com-
pared with controls, as well as the Alistipes species. Many
studies have found differences between severe and milder
cases of IBD, and others have seen differences between
patients pre- and post-treatment. These findings have made
it clear that there is a complicated and multifaceted rela-
tionship between the disease and the microbiome, though
whether the microbiome plays a cause or an effect role, or
perhaps a mixture of the two, has yet to be definitively
proven.
Changes in IBD from a Healthy Microbiome
As has also been observed in adult cohorts, children with IBD
have a different microbiome than their healthy counterparts. A
number of different bacteria have been found to be significantly
changed in paediatric IBD patients, compared to controls.
Table 1 contains a number of bacteria which have been found
to be differentially abundant in paediatric IBD patients when
compared with controls, as well as highlighting some of the
microbial differences seen between UC and CD, and between
varying disease states. Among those found to be decreased in
paediatric IBD compared with controls are members of the
Bifidobacterium genus [29, 42, 43, 45], which are commonly
considered gut commensals and markers of a healthy gut.
Specifically, both Bifidobacterium longum and Bifidobacterium
pseudocatenulatum were decreased in paediatric IBD patients
[45]. Most commonly reduced in paediatric IBD subjects are
bacteria from the Firmicutes phylum, including the family
Ruminococcaceae, and the genera Eubacterium and
Clostridium [29, 42, 43, 45, 46], consistent with findings in adult
IBD [47].
Although many studies do report similar findings in terms
of which bacterial changes are seen, there are a small number
of cases where findings differ across studies. For example,
Ruminococcaceae is generally reported as reduced in IBD
subjects [45, 48] but in Assa et al., an increase was seen in
those with IBD [49]. Of course, inter-study variation may
partially be a result of differences between the study designs,
such as differences in DNA extraction methods, sequencing,
analysis, and of course the type of sample, be that a stool
sample or a biopsy (from varying locations) [50]. Moreover,
a large inter-continental study of adult IBD recently highlight-
ed geographical changes, in terms of different lifestyle, diet
and ethnicity, to account for much of the observed microbiota
heterogeneity [31].
Although a reduction in microorganisms considered ‘bene-
ficial’ is the most striking difference of the microbiome in
paediatric IBD, other species appear to colonise the paediatric
IBD gut microbiome. Escherichia coli has often found to be
increased in paediatric IBD vs controls [42, 46, 51].
Interestingly, a number of studies have found bacteria typical
of the oral microbiome to be increased in paediatric IBD vs
controls, and in cases of severe vsmild IBD in children [29, 30,
48]. There is speculation that these species may be taking ad-
vantage of the changed environment, or potentially exasperat-
ing or driving (by inducing T helper cells) inflammation in the
guts of patients with IBD [30, 52, 53]. Many of these bacteria
are anaerobic, such as Veillonellaceae and Fusobacterium, or
facultative anaerobes, such as Haemophilus parainfluenzae, a
member of the Pasteurellaceae family.
Disease States and Severity in Paediatric IBD
Variation in microbial composition can also be seen across
disease states and varying with disease severity, where the
gut microbiome of children with mild IBD appears closer to
healthy microbiome than for more severe IBD cases. Disease
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severity is often evaluating using specific scoring metrics such
as the Paediatric Crohn’s Disease Activity Index (PCDAI)
[54], the Mayo score [55], and the Paediatric Ulcerative
Colitis Activity Index (PUCAI) [56]. These scoring systems
generally take into account the impact of the disease on the
patient, the disease burden, and disease course [57]. For in-
stance, Ruminococcus gnavus, a gut coccus with a potential
inflammatory role [58], was increased in children with total or
ileocolitis compared to those with colonic CD or left-sidedUC
[29]. This taxa was also particularly enriched in the guts of
paediatric IBD patients with increased disease activity [59].
Henke and co-authors proposed that this may be a result of a
glucorhamnan polysaccharide synthesised and secreted by
Ruminococcus gnavus, thereby promoting inflammation
through the induced secretion of TNFalpha, which is depen-
dent on the toll-like receptor 4 (TLR4) [58].
Furthermore, Veillonella was increased in paediatric CD
patients who had upper gastro manifestations [29]. Specific
strains of these, Veillonella dispar and Veillonella parvula, as
well as other oral cavity bacteria such as Haemophilus
parainfluenzae, were also found to be increased in severe
disease [30]. Interestingly, Haemophilus parainfluenzae was
detected at high levels in severe UC disease with drastic re-
ductions over treatment time, and appeared to correlate with
paediatric patients who would then enter remission. However,
children with mild disease and less but consistent abundance
of Haemophilus parainfluenzae were less likely to enter re-
mission. Schirmer and colleagues hypothesised that this may
mean a decrease in certain key bacteria, such as Haemophilus




Although there is no cure available for CD or UC, a number of
treatments are available for inducing remission. These treat-
ment options vary depending on disease severity and disease
type, and often have a significant effect on the microbiome.
For mild to moderate IBD, 5-aminosalicylic acid (5-ASA) or
antibiotic therapy have been used to induce remission [5],
which in some studies appears to affect the gut microbiome
[30]. The same authors also implicated several bacterial taxa,
previously associated with disease severity, with antibiotic
usage in paediatric UC patients [30]. These results were ech-
oed in a previous study on paediatric CD that found antibiotic
usage to increase microbiome dysbiosis in CD [48]. Antibiotic
usage was also associated with both bacterial and fungal
dysbiosis in a cohort of paediatric CD patients by Lewis
et al. [60]. These findings, along with studies examining anti-
biotics as potential causative agents in the general paediatric
population [61] and observational studies linking antibiotic
usage in children to an increased risk of developing IBD
[62, 63], highlights the need for further study of the long-
term effects on paediatric IBD gut post-antibiotic-induced
remission.
Corticosteroids, biologic therapy (anti-TNF agents such as
infliximab, often for non-responders to traditional treatments),
and thiopurines are used to treat children with UC and CD for
moderate to severe disease [5]. Steroid treatment, however,
comes with additional risk for paediatric patients, as it is im-
perative to avoid stunting growth in children who may already
be at risk of growth retardation due to malnutrition, particu-
larly patients with CD. Schirmer and colleagues also found 47
taxa associated with corticosteroids, whereof a majority were
correlated with both remission and non-remission groups,
raising the question of whether these changes in microbial
composition are a by-product of treatment, or a driving factor
in the efficacy of the treatment of IBD [30]. The interaction
between biological therapies, such as anti-TNF, and the
microbiome has not been extensively documented in paediat-
ric IBD patients. However, Firmicutes and Mycoplasma
hominiswere decreased in paediatric IBD patients treated with
biologic therapy compared with conventional methods (EEN
in CD, and steroids and 5-ASA in CD and UC) [29]. No
reduction in fungal colonisation in paediatric CD following
treatment with anti-TNF has been observed [60].
In addition to medication-based treatments, both diet inter-
ventions and surgery are commonly used in the treatment of
IBD. Special diets are found to help in CD, such as exclusive
enteral nutrition (EEN), partial enteral nutrition (PEN) with a
free diet, and CD exclusion diets (CDED). In Europe, EEN is
currently recommended as first-line treatment for new cases
[64]. These diets can have a profound effect on the
microbiome, and microbial changes associated with treatment
diets have been found in a multitude of IBD studies. Lewis
and co-authors found that the microbiome composition of
paediatric CD patients who responded to EEN was more sim-
ilar to healthy controls than those who did not respond to EEN
treatment. The authors also observed decreased fungal coloni-
sation after EEN treatment [60] and Haemophilus species (as-
sociated with disease severity in paediatric UC [30]). The
genus Alistipes was further increased in children receiving
EEN but negatively associated with antibiotic treatment. In
particular, Alistipes finegoldiii and Alistipes putredinus were
decreased in paediatric CD patients, but these increased with
EEN treatment (EEN was only given to CD patients) [46].
Escherichia coli has also been reported to be negatively asso-
ciated with EEN treatment, indicating a shift towards a more
‘healthy’ microbiome with this treatment [46]. The authors
also observed these trends in UC patients, who were treated
with either aminosalicylates or aminosalicylates and cortico-
steroids. It is worth noting that those on EEN in this study
were also receiving thiopurines [46]. In contrast, Quince and
colleagues found that the microbiota did not return to that seen
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in healthy controls after successful treatment of CDwith EEN,
but to a distinct state [65].
Although EEN is an effective treatment for CD in paediat-
ric patients (especially those with mild to moderate disease),
one major shortcoming of the treatment is implementation due
to low tolerance of the diet. Due to the challenges of main-
taining a liquid diet for the time required, as well as a possible
reversion seen when returning to a ‘free’ diet, a recently pro-
posed treatment regimen is a so-called CD exclusion diet
(CDED), which involves a whole food diet combined with
partial enteral nutrition (PEN). Levine and colleagues reported
that EEN and CDED resulted in similar levels of remission
achievement at week 6 of a 12-week study, but CDED was
more likely to have sustained remission at week 12 [66].
Similar species alterations were observed in the two treatment
groups at week 6 (decreases in Proteobacteria, Haemophilus,
Veillonella (which may be linked to lactate presence as these
are lactate-utilising bacteria), Bifidobacterium, Prevotella,
and Anaerostipes and increases in Oscillibacter and
Roseburia). However, at week 12, those on EEN appeared
to rebound to pre-treatment levels. These divergences once
EEN patients began to transition back to a free diet suggest
that CDED may be a more sustainable treatment strategy for
paediatric CD [66]. Another study investigating CD exclusion
diets in IBD had similar findings regarding achieving remis-
sion in EEN and CDED in adult CD subjects and a small
number of paediatric CD subjects [67].
Surgery is often a treatment option of last resort for refrac-
tory disease. Twenty-one OTUs (operational taxonomic unit,
represents a taxonomic unit of a bacterial species or genus,
clustered by sequence similarity) were associated a colectomy
being required in later treatment for paediatric UC patients,
and three of the OTUs that were increased were oral bacteria,
which were also associated with severe disease. Twelve of
those decreased were also depleted in those with severe dis-
ease [30]. Higher abundances of Proteobacteria and lower
Faecalibacterium prausnitziiwere found to be associatedwith
surgery and a lack of mucosal healing in paediatric IBD [29].
Decreased levels Faecalibacterium prausnitzii have also been
observed in resected adult IBD patients [31]. The findings in
these studies may suggest that certain bacteria could be used
as identifying markers in patients who would become medical
non-responders at a later point.
Faecal microbiota transplantation (FMT) may also be a po-
tential treatment option for paediatric IBD, though it is currently
not widely utilised [68]. Adult IBD studies (CD and UC) have
shown success using FMT, with some patients achieving remis-
sion or showing a clinical response [69, 70]. Although a smaller
number of studies are available for paediatric CD and UC, there
has been some therapeutic potential suggested [71, 72].
However, other studies found that although safe, FMT did not
provide any clinical benefit for some patients (adult mild to mod-
erate UC [70], and paediatric UC [73]).
The Virome
The viruses in the gut (the gut virome) have not been studied
to the same degree as the bacteria in the gut, including those
studies targeting IBD. However, it has been suggested that
different abundances in the bacteriophages in the gut may also
play a role in IBD [74]. The viral taxa found to be most
abundant in the gut of both children and adults, irrespective
of disease status, were Caudovirales and Microviridae [74,
75]. Increased richness and diversity of Caudovirales was
observed in adult IBD compared with controls [74], and in-
creased Caudovirales abundance has been reported in paedi-
atric CD compared with UC [75]. This increase in
Caudovirales was not detected in paediatric CD compared
with healthy controls [60]. While increased richness of
Microviridae in controls was observed compared to paediatric
CD [75], this was not replicated in a more recent study, where
no increased richness in adult UC or CD was seen when com-
pared to controls [76]. The authors did however report in-
creased diversity of Caudovirales in CD patients, but this
was not seen in UC. Here, a significantly increased number
of temperature phages in CD when compared with healthy
controls [76].
Mycobiome
The fungal microbiota, or mycobiome, though also less
investigated than the bacterial microbiota, may show dif-
ferences in the IBD gut when compared with healthy in-
dividuals. While several number of studies have observed
changes in the fungal profile of IBD patients compared to
healthy controls [60, 77, 78], these changes are not uni-
form between studies. An increased fungal abundance
overall was observed in paediatric CD [60], and an in-
creased fungal biodiversity was reported in CD, but not
UC [77]. In contrast, Chehoud and colleagues reported
reduced fungal diversity in paediatric IBD [79]. An adult
cohort [77] and a small paediatric cohort [78] both report-
ed Basidiomycota to be more abundant in IBD, with a
corresponding decrease in Ascomycota. Malassezia (pri-
marily Malassezia restricta) was found to be associated
with CD, and responsible for the increase in basidiomy-
cetes seen in the Limon et al. cohort of adult CD patients.
Malassezia restricta was linked to adult CD patients with
a disease-linked polymorphism in CARD9, and was found
to exacerbate colitis in mouse models [80]. However, an-
other study found fungi from the Ascomycota phylum to
be increased in paediatric CD [60], as well as Candida
albicans, which was also increased in adult IBD [77].
Another taxa, Cyberlindnera jadinii, was increased in
paediatric IBD compared with controls [60, 79].
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Oral Microbiome
Though UC is generally limited to the colon, CD can occur
anywhere in the gastrointestinal tract, and can include involve-
ment of the oral cavity, with approximately 40% of a cohort of
Irish paediatric CD patients (over a 3 year period) having oral
involvement [81]. A significant decrease in diversity was seen
in tongue samples of paediatric CD patients when compared
to healthy and though non-significant, a decrease was also
seen in the buccal samples of these paediatric CD patients
[82]. Tongue samples in CD also showed a decrease in
Fusobacteria and Firmicutes, but no phylum changes were
observed in the buccal samples [82]. No difference in diversity
was observed in UC patients in the tongue or buccal samples
when compared with healthy, but certain bacterial changes
were observed in tongue samples, namely a decrease in
Fusobacteria and increased levels of Spirochaetes,
Synergistetes, and Bacteroidetes [82]. As previously men-
tioned, increased numbers of oral bacteria have been observed
in the gut of IBD vs healthy individuals, and in IBD patients
with increased disease severity. This could suggest that an
invasion of oral bacteria to the gut may contribute to part of
the dysbiosis observed.
Conclusion
Paediatric IBD is a lifelong condition (currently with no med-
ical cure) and can have a severe impact on the quality of life of
those suffering from the disease. The incidence and preva-
lence of paediatric IBD is rising, for both CD and UC, and
the prevalence is particularly high in industrialised countries.
The aetiology of IBD is unknown though it is thought that
there is a genetic element, as well as environmental risks, such
as industrialisation, and a western lifestyle. The microbiome is
also believed to contribute to the risk of developing IBD.
Studies have also shown that both CD and UC have
microbiomes that are significantly different from healthy indi-
viduals and it is clear from the literature that the microbiome and
IBD have a varied and complex relationship. There is some
disagreement on whether the healthy paediatric microbiome is
identical to the adult microbiome, with arguments on both sides.
However, both adult and paediatric IBD exhibit significant dif-
ferences between disease and healthy controls. There is a de-
crease in bacterial diversity seen in the guts of IBD patients
compared to controls. A number of bacteria, particularly com-
mensals, have been reduced in paediatric IBD compared with
controls, such as the Bifidobacterium genus and those in the
Firmicutes phylum, such as those from the genera
Eubacterium, Ruminococcaceae, and Clostridium. Escherichia
coli and various oral bacteria, such as Veillonellaceae,
Fusobacterium, and Haemophilus parainfluenzae appear to be
increased in paediatric IBD.
Significant differences in microbial composition are evi-
dent in the different disease states and disease severity levels,
like oral cavity bacteria (such asHaemophilus parainfluenzae)
which were found to be increased with disease severity.
Possible future research in this area may focus on whether
the bacterial changes seen with increased disease severity are
an outcome of the worsening disease or if the bacteria have the
potential to be contributing to the changes in disease state or
severity.
Treatments for IBD appear to have at least some impact on
the microbiome, whether that is an intentional effect or a by-
product of treatment. Antibiotics have been found to increase
dysbiosis in both paediatric CD and UC, and microbes asso-
ciated with disease severity have also been linked to antibiotic
usage by studies. Both 5-ASAs and corticosteroids have been
linked to changes in the microbiome and biological therapies
such as anti-TNF may be linked to decreases in Firmicutes.
Diet therapy, such as EEN, is extensively used as a treatment
in paediatric CD. EEN was found to move paediatric CD
patients closer to a healthy control microbiome in some stud-
ies, but to a distinct pattern of microbiota in others, and some
bacteria were also reported to be changed with EEN therapy.
An emerging diet therapy, CDED, was found to have similar
microbiome changes as EEN treatment (such as
Proteobacteria decreases). The CDED study shows promise
for dietary treatments in paediatric patients without resorting
to an entirely enteral diet.
Investigation of the oral microbiome is also worth consid-
ering as up to 40% of paediatric CD patients in one study had
oral involvement. Decreases in diversity were found in tongue
samples from paediatric CD, and both CD and UC had de-
creased Fusobacteria in tongue samples when compared to
controls. Given the number of studies identifying oral bacteria
in the gut of paediatric IBD patients, research into whether the
oral bacteria may be invading the gut and contributing to the
dysbiosis observed may be a future area of interest.
Less well studied, but a potential future area of interest are
the other gut biomes in IBD: the virome and the mycobiome.
The virome in IBD is a relatively unexplored area of research,
and some disparity exists between the results so far, such as
the possibility of increased Caudovirales in IBD. Though cur-
rently not extensively explored, a number of studies suggest
that there may be significant changes in the mycobiome of
IBD patients, and that fungal microbes may be more abundant
in CD. Increased Basidiomycota has been reported in paedi-
atric IBD patients, as well as increased abundances of species
such as Cyberlindnera jadinii and Candida albicans.
Research into the paediatric IBD microbiome over the last
number of years has yielded a large amount of new knowledge
about the role microorganisms may play in the aetiology and
pathology of CD and UC. These studies have great clinical
significance and the accumulation of this knowledge is essen-
tial to gain a deeper understanding of the development and
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mechanisms of these serious conditions, as well as being cru-
cial for the development of advancements in the treatment
options for CD and UC.
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